ESMO Press Releases

Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.

The finding that breast tumours can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumours.

ESMO Breast 2021 Virtual is designed for breast cancer researchers and clinicians who have a specific interest in innovation (including translational research, new agents, molecular and functional diagnostics, biomarkers and cutting-edge research applications in the clinical setting) and care. It will be a multidisciplinary European Congress involving top scientists.

ESMO/SIOPE expert position paper raises awareness of need for age-appropriate specialist services to improve cancer outcomes

Clinical activity with a second drug inhibiting KRAS^G12C confirms its role as a therapeutic target in patients with advanced non-small-cell lung cancer (NSCLC) harbouring this mutation, according to results from a study with the KRAS^G12C inhibitor adagrasib reported at the European Lung Cancer Virtual Congress 2021.

The increasing complexity of treatments for lung cancer and language differences can make it difficult for patients to communicate with their medical teams

The European Lung Cancer Congress 2021, the annual event devoted to advance the quality of lung cancer treatment, will be held as a virtual meeting.

The ESMO Targeted Anticancer Therapies Congress 2021, designed for basic scientists, physicians and translational researchers belonging to academic settings, industry and regulatory agencies will be held as a virtual meeting.

Researchers Predict Over 1.4 Million Deaths From Top 10 Cancers in 2021 in the EU and UK. Accompanying Editorial Warns of Adverse Effect of COVID-19 on Death Rates.